|
業務類別
|
Biotechnology |
|
業務概覽
|
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy. |
| 公司地址
| 5217 Winnebago Lane, Austin, TX, USA, 78744 |
| 電話號碼
| +1 512 386-2900 |
| 傳真號碼
| +1 512 386-5505 |
| 公司網頁
| http://www.xbiotech.com |
| 員工數量
| 85 |
| Ms. Angela Hu |
Director of Finance, Principal Financial Officer and Principal Accounting Officer |
美元 200.00K |
13/03/2026 |
| Ms. Sushma Shivaswamy |
Chief Scientific Officer and Interim Chief Executive Officer |
美元 450.00K |
13/03/2026 |
|
|
| Dr. Tevi David Troy, M.A. |
Independent Director |
13/03/2026 |
| Dr. Thomas Kundig |
Director |
13/03/2026 |
| Dr. David Spencer Soffer |
Independent Director |
13/03/2026 |
| Mr. Craig Evan Rademaker |
Director |
13/03/2026 |
| Mr. John Simard |
Chairman of the Board |
13/03/2026 |
| Mr. Jan-Paul Waldin, Esq. |
Lead Independent Director |
07/07/2025 |
| Dr. Peter Libby, M.D. |
Independent Director |
07/07/2025 |
| Dr. Tak W. Mak |
Director |
07/07/2025 |
|
|
|
|
